New eczema drug shows promise in early trial
NCT ID NCT07220577
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2a study tests a new drug called GIA632 in 34 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it safely improves skin symptoms compared to a placebo. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doctors know which they get.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GIA632
What this could lead to
If it works, this could point toward a new treatment option for people with moderate to severe eczema.
What could go wrong
This is an early Phase 2a study with only 34 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aesthetics Skin Care Dermatologic Surgery
Rockville, Maryland, 20850, United States
-
Care Access Hoboken
Hoboken, New Jersey, 07030, United States
-
Ctr for Dermatology Clinical Res
Fremont, California, 95438, United States
-
Novartis Investigative Site
Ipoh, Perak, 30450, Malaysia
-
Novartis Investigative Site
George Town, Pulau Pinang, 10450, Malaysia
-
Novartis Investigative Site
Kota Kinabalu, Sabah, 88586, Malaysia
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Gdansk, 80-546, Poland
-
Novartis Investigative Site
Torun, 87-100, Poland
-
Novartis Investigative Site
Warsaw, 00-872, Poland
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Singapore, 308205, Singapore
-
Novartis Investigative Site
Pleven, 5800, Bulgaria
-
Novartis Investigative Site
Sofia, 1202, Bulgaria
-
Novartis Investigative Site
Sofia, 1618, Bulgaria
-
Novartis Investigative Site
Toronto, Ontario, M5A 3R6, Canada
-
Novartis Investigative Site
Québec, Quebec, G1W 4R4, Canada
-
Novartis Investigative Site
Ostrava, Poruba, 708 52, Czechia
-
Novartis Investigative Site
Brno, 602 00, Czechia
-
Novartis Investigative Site
Prague, 100 34, Czechia
-
Novartis Investigative Site
Antony, 92160, France
-
Novartis Investigative Site
Dijon, 21000, France
-
Novartis Investigative Site
Martigues, 13500, France
-
Novartis Investigative Site
Nice, 06000, France
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Hamburg, 20095, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany